A Genome-wide RNAi Screen for Polypeptides that Alter rpS6 Phosphorylation View Full Text


Ontology type: schema:Chapter      Open Access: True


Chapter Info

DATE

2011-09-29

AUTHORS

Angela Papageorgiou , Joseph Avruch

ABSTRACT

Mammalian target of rapamycin (mTOR) is a giant protein kinase that controls cell proliferation, growth, and metabolism. mTOR is regulated by nutrient availability, by mitogens, and by stress, and operates through two independently regulated hetero-oligomeric complexes. We have attempted to identify the cellular components necessary to maintain the activity of mTOR complex 1 (mTORC1), the amino acid-dependent, rapamycin-inhibitable complex, using a whole genome approach involving RNAi-induced depletion of cellular polypeptides. We have used a pancreatic ductal adenocarcinoma (PDAC) cell line, Mia-PaCa for this screen; as with many pancreatic cancers, these cells exhibit constitutive activation of mTORC1. PDAC is the most common form of pancreatic cancer and the 5-year survival rate remains 3–5% despite current nonspecific and targeted therapies. Although rapamycin-related mTOR inhibitors have yet to demonstrate encouraging clinical responses, it is now evident that this class of compounds is capable of only partial mTORC1 inhibition. Identifying previously unappreciated proteins needed for maintenance of mTORC1 activity may provide new targets and lead to the development of beneficial therapies for pancreatic cancer. More... »

PAGES

187-214

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-61779-430-8_11

DOI

http://dx.doi.org/10.1007/978-1-61779-430-8_11

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034538880

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22125066


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Pancreatic Ductal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorescent Antibody Technique", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genome, Human", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mechanistic Target of Rapamycin Complex 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiprotein Complexes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA Interference", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribosomal Protein S6", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TOR Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transfection", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Harvard Medical School, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "Diabetes Unit and Medical Services and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA", 
            "Department of Medicine, Harvard Medical School, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papageorgiou", 
        "givenName": "Angela", 
        "id": "sg:person.0702604521.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702604521.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Harvard Medical School, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "Diabetes Unit and Medical Services and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA", 
            "Department of Medicine, Harvard Medical School, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Avruch", 
        "givenName": "Joseph", 
        "id": "sg:person.01074100404.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074100404.77"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-09-29", 
    "datePublishedReg": "2011-09-29", 
    "description": "Mammalian target of rapamycin (mTOR) is a giant protein kinase that controls cell proliferation, growth, and metabolism. mTOR is regulated by nutrient availability, by mitogens, and by stress, and operates through two independently regulated hetero-oligomeric complexes. We have attempted to identify the cellular components necessary to maintain the activity of mTOR complex 1 (mTORC1), the amino acid-dependent, rapamycin-inhibitable complex, using a whole genome approach involving RNAi-induced depletion of cellular polypeptides. We have used a pancreatic ductal adenocarcinoma (PDAC) cell line, Mia-PaCa for this screen; as with many pancreatic cancers, these cells exhibit constitutive activation of mTORC1. PDAC is the most common form of pancreatic cancer and the 5-year survival rate remains 3\u20135% despite current nonspecific and targeted therapies. Although rapamycin-related mTOR inhibitors have yet to demonstrate encouraging clinical responses, it is now evident that this class of compounds is capable of only partial mTORC1 inhibition. Identifying previously unappreciated proteins needed for maintenance of mTORC1 activity may provide new targets and lead to the development of beneficial therapies for pancreatic cancer.", 
    "editor": [
      {
        "familyName": "Weichhart", 
        "givenName": "Thomas", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-61779-430-8_11", 
    "isAccessibleForFree": true, 
    "isPartOf": {
      "isbn": [
        "978-1-61779-429-2", 
        "978-1-61779-430-8"
      ], 
      "name": "mTOR", 
      "type": "Book"
    }, 
    "keywords": [
      "genome-wide RNAi screen", 
      "giant protein kinases", 
      "RNAi-induced depletion", 
      "hetero-oligomeric complexes", 
      "mTOR complex 1", 
      "whole-genome approach", 
      "RNAi screen", 
      "protein kinase", 
      "cellular polypeptides", 
      "genome approach", 
      "nutrient availability", 
      "pancreatic ductal adenocarcinoma cell lines", 
      "rpS6 phosphorylation", 
      "constitutive activation", 
      "cellular components", 
      "mammalian target", 
      "adenocarcinoma cell line", 
      "cell proliferation", 
      "cell lines", 
      "new targets", 
      "polypeptide", 
      "mTOR inhibitors", 
      "MIA PaCa", 
      "pancreatic cancer", 
      "complexes 1", 
      "kinase", 
      "complexes", 
      "phosphorylation", 
      "screen", 
      "mTOR", 
      "rapamycin", 
      "protein", 
      "target", 
      "mitogen", 
      "metabolism", 
      "proliferation", 
      "class of compounds", 
      "activity", 
      "cells", 
      "activation", 
      "inhibitors", 
      "cancer", 
      "common form", 
      "inhibition", 
      "growth", 
      "maintenance", 
      "depletion", 
      "PDAC", 
      "stress", 
      "availability", 
      "lines", 
      "survival rate", 
      "response", 
      "development", 
      "components", 
      "compounds", 
      "form", 
      "nonspecific", 
      "encouraging clinical responses", 
      "class", 
      "clinical response", 
      "beneficial therapy", 
      "rate", 
      "therapy", 
      "approach"
    ], 
    "name": "A Genome-wide RNAi Screen for Polypeptides that Alter rpS6 Phosphorylation", 
    "pagination": "187-214", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034538880"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-61779-430-8_11"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22125066"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-61779-430-8_11", 
      "https://app.dimensions.ai/details/publication/pub.1034538880"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_129.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-61779-430-8_11"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-430-8_11'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-430-8_11'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-430-8_11'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-61779-430-8_11'


 

This table displays all metadata directly associated to this object as RDF triples.

208 TRIPLES      22 PREDICATES      108 URIs      101 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-61779-430-8_11 schema:about N0a3f198f7dbc45e8b9199141097edd11
2 N135e6a1efb264ca28c2375e6390053be
3 N29fdf8b0960646b6add15460b1dc9605
4 N2b18c9ce98fe434fb3978144a710738b
5 N35f038c2f9c04b16becd5201ddd16998
6 N516739ccda9c4745b400f135e99a119f
7 N6a444d8bdd824aeb80979429f3173bfd
8 N6e7c7ba27fb6406bbf7e337c97cd3c55
9 N7c80df030cee4151951d624002fc9f10
10 N85492e109dea4ef784d1af5fcab0be04
11 N8d2bf90e6ea9451095ece8736dd64bb0
12 N9bf2236e65ba4265a9f9e6e155dfb620
13 Nb22c481c0c16410882eaaf9b6f64dbc1
14 Nb48677a3023c44dfb582536b9f2ff9ae
15 Nb5973efddcd047b7b78616baec00a822
16 Nc574cef154b94835b5066bff32609e7e
17 Nc8a69a63a1924e648fefd8c58c0c05d8
18 Nec65ad857d234e8aab8e0a75978eec08
19 anzsrc-for:06
20 anzsrc-for:0601
21 schema:author Naeffe66496644d66ac2f6e3f0114a3b5
22 schema:datePublished 2011-09-29
23 schema:datePublishedReg 2011-09-29
24 schema:description Mammalian target of rapamycin (mTOR) is a giant protein kinase that controls cell proliferation, growth, and metabolism. mTOR is regulated by nutrient availability, by mitogens, and by stress, and operates through two independently regulated hetero-oligomeric complexes. We have attempted to identify the cellular components necessary to maintain the activity of mTOR complex 1 (mTORC1), the amino acid-dependent, rapamycin-inhibitable complex, using a whole genome approach involving RNAi-induced depletion of cellular polypeptides. We have used a pancreatic ductal adenocarcinoma (PDAC) cell line, Mia-PaCa for this screen; as with many pancreatic cancers, these cells exhibit constitutive activation of mTORC1. PDAC is the most common form of pancreatic cancer and the 5-year survival rate remains 3–5% despite current nonspecific and targeted therapies. Although rapamycin-related mTOR inhibitors have yet to demonstrate encouraging clinical responses, it is now evident that this class of compounds is capable of only partial mTORC1 inhibition. Identifying previously unappreciated proteins needed for maintenance of mTORC1 activity may provide new targets and lead to the development of beneficial therapies for pancreatic cancer.
25 schema:editor N1f24db072b1d4fefbae91374641a1105
26 schema:genre chapter
27 schema:isAccessibleForFree true
28 schema:isPartOf N7f2e81d339254517880f84edebaae41e
29 schema:keywords MIA PaCa
30 PDAC
31 RNAi screen
32 RNAi-induced depletion
33 activation
34 activity
35 adenocarcinoma cell line
36 approach
37 availability
38 beneficial therapy
39 cancer
40 cell lines
41 cell proliferation
42 cells
43 cellular components
44 cellular polypeptides
45 class
46 class of compounds
47 clinical response
48 common form
49 complexes
50 complexes 1
51 components
52 compounds
53 constitutive activation
54 depletion
55 development
56 encouraging clinical responses
57 form
58 genome approach
59 genome-wide RNAi screen
60 giant protein kinases
61 growth
62 hetero-oligomeric complexes
63 inhibition
64 inhibitors
65 kinase
66 lines
67 mTOR
68 mTOR complex 1
69 mTOR inhibitors
70 maintenance
71 mammalian target
72 metabolism
73 mitogen
74 new targets
75 nonspecific
76 nutrient availability
77 pancreatic cancer
78 pancreatic ductal adenocarcinoma cell lines
79 phosphorylation
80 polypeptide
81 proliferation
82 protein
83 protein kinase
84 rapamycin
85 rate
86 response
87 rpS6 phosphorylation
88 screen
89 stress
90 survival rate
91 target
92 therapy
93 whole-genome approach
94 schema:name A Genome-wide RNAi Screen for Polypeptides that Alter rpS6 Phosphorylation
95 schema:pagination 187-214
96 schema:productId N1d3235d9f90f4db08acdb568b9cb5e79
97 Nb5d5d82d16f140a79a741d345577c3f4
98 Nf5cd44e51b0f464c955298cc8778ac44
99 schema:publisher N37fa5840e93a470fa3282b7a6c2cfeb8
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034538880
101 https://doi.org/10.1007/978-1-61779-430-8_11
102 schema:sdDatePublished 2022-10-01T06:52
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher N0ea48c35374147569b7d831d36015ae5
105 schema:url https://doi.org/10.1007/978-1-61779-430-8_11
106 sgo:license sg:explorer/license/
107 sgo:sdDataset chapters
108 rdf:type schema:Chapter
109 N0a3f198f7dbc45e8b9199141097edd11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Signal Transduction
111 rdf:type schema:DefinedTerm
112 N0ea48c35374147569b7d831d36015ae5 schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 N135e6a1efb264ca28c2375e6390053be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Pancreatic Neoplasms
116 rdf:type schema:DefinedTerm
117 N1d3235d9f90f4db08acdb568b9cb5e79 schema:name pubmed_id
118 schema:value 22125066
119 rdf:type schema:PropertyValue
120 N1f24db072b1d4fefbae91374641a1105 rdf:first Nf8729bb0f09b42ffad253f2e50c41fee
121 rdf:rest rdf:nil
122 N29fdf8b0960646b6add15460b1dc9605 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Cell Line, Tumor
124 rdf:type schema:DefinedTerm
125 N2b18c9ce98fe434fb3978144a710738b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name RNA Interference
127 rdf:type schema:DefinedTerm
128 N35f038c2f9c04b16becd5201ddd16998 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Proteins
130 rdf:type schema:DefinedTerm
131 N37fa5840e93a470fa3282b7a6c2cfeb8 schema:name Springer Nature
132 rdf:type schema:Organisation
133 N516739ccda9c4745b400f135e99a119f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Genome, Human
135 rdf:type schema:DefinedTerm
136 N6a444d8bdd824aeb80979429f3173bfd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Ribosomal Protein S6
138 rdf:type schema:DefinedTerm
139 N6e7c7ba27fb6406bbf7e337c97cd3c55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Sirolimus
141 rdf:type schema:DefinedTerm
142 N7c80df030cee4151951d624002fc9f10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Humans
144 rdf:type schema:DefinedTerm
145 N7f2e81d339254517880f84edebaae41e schema:isbn 978-1-61779-429-2
146 978-1-61779-430-8
147 schema:name mTOR
148 rdf:type schema:Book
149 N85492e109dea4ef784d1af5fcab0be04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Phosphorylation
151 rdf:type schema:DefinedTerm
152 N85c6bad1474541b69c493218837b0e89 rdf:first sg:person.01074100404.77
153 rdf:rest rdf:nil
154 N8d2bf90e6ea9451095ece8736dd64bb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Mechanistic Target of Rapamycin Complex 1
156 rdf:type schema:DefinedTerm
157 N9bf2236e65ba4265a9f9e6e155dfb620 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Cell Proliferation
159 rdf:type schema:DefinedTerm
160 Naeffe66496644d66ac2f6e3f0114a3b5 rdf:first sg:person.0702604521.95
161 rdf:rest N85c6bad1474541b69c493218837b0e89
162 Nb22c481c0c16410882eaaf9b6f64dbc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Adenocarcinoma
164 rdf:type schema:DefinedTerm
165 Nb48677a3023c44dfb582536b9f2ff9ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Transfection
167 rdf:type schema:DefinedTerm
168 Nb5973efddcd047b7b78616baec00a822 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Carcinoma, Pancreatic Ductal
170 rdf:type schema:DefinedTerm
171 Nb5d5d82d16f140a79a741d345577c3f4 schema:name dimensions_id
172 schema:value pub.1034538880
173 rdf:type schema:PropertyValue
174 Nc574cef154b94835b5066bff32609e7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Multiprotein Complexes
176 rdf:type schema:DefinedTerm
177 Nc8a69a63a1924e648fefd8c58c0c05d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name TOR Serine-Threonine Kinases
179 rdf:type schema:DefinedTerm
180 Nec65ad857d234e8aab8e0a75978eec08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Fluorescent Antibody Technique
182 rdf:type schema:DefinedTerm
183 Nf5cd44e51b0f464c955298cc8778ac44 schema:name doi
184 schema:value 10.1007/978-1-61779-430-8_11
185 rdf:type schema:PropertyValue
186 Nf8729bb0f09b42ffad253f2e50c41fee schema:familyName Weichhart
187 schema:givenName Thomas
188 rdf:type schema:Person
189 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
190 schema:name Biological Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
193 schema:name Biochemistry and Cell Biology
194 rdf:type schema:DefinedTerm
195 sg:person.01074100404.77 schema:affiliation grid-institutes:grid.38142.3c
196 schema:familyName Avruch
197 schema:givenName Joseph
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074100404.77
199 rdf:type schema:Person
200 sg:person.0702604521.95 schema:affiliation grid-institutes:grid.38142.3c
201 schema:familyName Papageorgiou
202 schema:givenName Angela
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702604521.95
204 rdf:type schema:Person
205 grid-institutes:grid.38142.3c schema:alternateName Department of Medicine, Harvard Medical School, Boston, MA, USA
206 schema:name Department of Medicine, Harvard Medical School, Boston, MA, USA
207 Diabetes Unit and Medical Services and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA
208 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...